Harvard Bioscience (HBIO) Cash from Financing Activities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash from Financing Activities data on file, last reported at -$9000.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$9000.0, up 99.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$96000.0 (up 65.71% YoY), and the FY2025 annual result was -$1.3 million, down 885.5% from the prior year.
• Cash from Financing Activities eased to -$9000.0 in Q1 2026 per HBIO's latest filing, from $2.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $2.4 million in Q4 2025 and troughed at -$4.1 million in Q4 2023.
• A 5-year average of -$964823.5 and a median of -$1.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 3177.66% in 2023, then jumped 280.47% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$2.7 million in 2022, then plunged by 50.77% to -$4.1 million in 2023, then surged by 67.03% to -$1.4 million in 2024, then jumped by 280.47% to $2.4 million in 2025, then plunged by 100.37% to -$9000.0 in 2026.
• Business Quant data shows HBIO's Cash from Financing Activities at -$9000.0 in Q1 2026, $2.4 million in Q4 2025, and -$1.3 million in Q3 2025.